Navigation Links
Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results
Date:3/18/2009

ies for the use of the Company's technology to evaluate compounds. This effort resulted in contracts including two with Centocor, Inc.
  • The Company entered into a royalty agreement with Concordia Pharmaceuticals to realize the potential upside value of Salirasib, Concordia's novel compound for the treatment of cancer, in combination with another targeted drug.
  • The Company established collaboration with Gradalis Inc. and Mary Crowley Medical Research Center to develop personalized vaccines for cancer patients through the use of the Biomerk Tumorgraft technology.
  • The Company grew the number of procedures within its Personalized Oncology business by 33% and has initiated processes to make this service more readily available in key international markets.
  • The Company continued to expand initiatives to develop its own drug pipeline. During the quarter numerous candidates were identified, due-diligence was performed, and the Company is currently in negotiations for acquisition or co-development of a number of agents.
  • For more information regarding Champions Biotechnology please visit our web site at www.championsbiotechnology.com.

    About Champions Biotechnology, Inc.

    Champions Biotechnology, Inc. is engaged in the development of advanced preclinical platforms and predictive tumor specific data to enhance and accelerate the value of oncology drugs. The Company's Preclinical Platform is a novel approach based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments (Biomerk Tumorgrafts(TM)) in a manner that preserves the biological characteristics of the original human tumor. Early studies suggest that these Tumorgrafts closely reflect human cancer biology and their response to drugs is predicti
    '/>"/>

    SOURCE Champions Biotechnology, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. Champions Biotechnology Reports Fiscal 2008 Full-Year Financial Results
    2. Champions Biotechnology and ImClone Systems Establish Agreement for Preclinical Evaluation of Oncology Drugs
    3. Champions Biotechnology, Inc. Completes $2,500,000 Private Financing at $1.75 per Share
    4. Champions Biotechnology, Inc. Appoints New Board Members and Forms Management Team
    5. Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award
    6. Dr. David Sidransky Appointed Chairman of Champions Biotechnology, Inc.
    7. Biotechnology Value Fund Urges Stockholders to Remove and Replace Current Board of Avigen, Inc. in an Effort to Protect and Maximize Stockholder Value
    8. Canadian Government Announces Funding for Leading Biotechnology Firms Project
    9. InNexus Biotechnology Announces New Patents Protecting Novel Cell Penetrating DXL(TM) Antibodies
    10. FDA Provides A Positive Review of InNexus Biotechnology Development Plan for Lead Product
    11. PDS Biotechnology Corporation Finalizes Commercial Licensing Agreement with Merck Eprova AG to Utilize Merck Eprovas Enantiomers of DOTAP Chloride in Immunotherapies
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/22/2014)... NEW YORK , Oct. 22, 2014 ... Diabetes Federation, approximately 400 million people worldwide are living ... 552 million people by 2030.  The global market for ... In 2012 approximately 330,000 people worldwide died from pancreatic ... of death due to cancer in the ...
    (Date:10/22/2014)... HONG KONG , Oct. 22, 2014  aTyr ... today that rare disease expert John C. McKew ... Dr. McKew brings more than two decades of expertise ... National Institutes of Health, Wyeth Research and Genetics Institute, ... lead aTyr,s efforts to expand and translate its novel ...
    (Date:10/20/2014)... Oct. 20, 2014 Mapp Biopharmaceutical,s valiant ... antibody therapeutic to fight the Ebola outbreak will ... time-consuming the production of pharmaceuticals can be, according ... said that while some may be taken aback ... those with industry knowledge are well aware of ...
    (Date:10/20/2014)... Oct. 20, 2014 Asterias Biotherapeutics, Inc. ... has signed a Notice of Grant Award (NGA) ... effective October 1, 2014.  The NGA provides for ... the release of additional grant funds pursuant to ... for clinical development of Asterias, product, AST-OPC1. The ...
    Breaking Biology Technology:Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4
    ... BioLife Solutions, Inc.,(OTC Bulletin Board: BLFS), ... hypothermic storage and cryopreservation media products for ... of its new quarterly,newsletter BioPreservation Today, a ... and processes, to maximize the yield and,function ...
    ... Md., Jan. 26 MaxCyte, Inc., the pioneer ... the presentation of the MaxCyte(R) STX(TM) Scalable Transfection ... Session, a joint program of the Association for ... Group (LRIG). The Rapid Fire Innovation Session showcases ...
    ... as subcontractor to Battelle for submission of proposals ... 26 Corgenix Medical Corporation (OTC Bulletin Board: ... test kits, has announced a collaboration with Battelle, ... whose business focus includes national security. Under the ...
    Cached Biology Technology:BioLife Solutions Launches BioPreservation Today(R) Industry Newsletter 2BioLife Solutions Launches BioPreservation Today(R) Industry Newsletter 3The MaxCyte(R) STX(TM) Scalable Transfection System to be Presented at the Rapid Fire Innovation Session at LabAutomation2009 2Corgenix Signs Collaboration With Battelle 2Corgenix Signs Collaboration With Battelle 3
    (Date:10/19/2014)... electricity access in India over the last 30 ... carbon emissions growth during that time, according to ... Nature Climate Change ., "Energy access is fundamental ... of life, including education, communication, and health," says ... , While increased energy access is widely agreed ...
    (Date:10/18/2014)... sample of patients with undiagnosed, suspected genetic conditions, a ... a higher molecular diagnostic yield than traditional molecular diagnostic ... . The study is being released to coincide with ... Exome sequencing, which sequences the protein­coding region of the ... present in a cell or organism), has been rapidly ...
    (Date:10/17/2014)... for the first time how bacteria can grow directly ... the opportunity to get tremendous insights into bacteria behavior ... discovered the bacterial growth in chronic lung infections among ... by the immune cells. The researchers discovered the immune ... bacteria, forcing the bacteria to switch to a much ...
    Breaking Biology News(10 mins):Improved electricity access has little impact on climate change 2Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2
    ... is available in German . , Four ... year,s Heinz Maier-Leibnitz Prize, Germany,s top research award for young ... the prize, which has been awarded annually by the Deutsche ... of Education and Research since 1977, that the majority of ...
    ... is available in German . The gene ... by cell division. It causes the production of a protein ... to 15 % of all human genes. When this gene ... is inhibited. Thereby the gene plays a decisive role in ...
    ... is a familiar phenomenon, even if the phrase is not: ... it around the block. After jogging regularly for a few ... three. With regular exercise, the body adapts, becoming fitter and ... oxygen to the muscles. The muscles get stronger, and so ...
    Cached Biology News:Heinz Maier-Leibnitz Prizes 2009: Six young researchers recognized for outstanding achievements 2Heinz Maier-Leibnitz Prizes 2009: Six young researchers recognized for outstanding achievements 3Heinz Maier-Leibnitz Prizes 2009: Six young researchers recognized for outstanding achievements 4Heinz Maier-Leibnitz Prizes 2009: Six young researchers recognized for outstanding achievements 5Symposium to look at genetic basis of exercise 2Symposium to look at genetic basis of exercise 3
    Human/Rat Neurogenin-2 MAb (Clone 7G4) Protein Family: Neural Crest Cell Markers, Transcription Factors...
    Rat CINC-2 alpha/beta Affinity Purified Polyclonal Ab...
    Monkey IL-2 ELISPOT Kit with white/opague microtiter plates...
    Mouse TREM-2 Affinity Purified Polyclonal Ab...
    Biology Products: